Saltar al contenido
Merck

Methionine is a metabolic dependency of tumor-initiating cells.

Nature medicine (2019-05-08)
Zhenxun Wang, Lian Yee Yip, Jia Hui Jane Lee, Zhengwei Wu, Hui Yi Chew, Pooi Kiat William Chong, Chin Chye Teo, Heather Yin-Kuan Ang, Kai Lay Esther Peh, Ju Yuan, Siming Ma, Li Shi Kimberly Choo, Nurhidayah Basri, Xia Jiang, Qiang Yu, Axel M Hillmer, Wan Teck Lim, Tony Kiat Hon Lim, Angela Takano, Eng Huat Tan, Daniel Shao Weng Tan, Ying Swan Ho, Bing Lim, Wai Leong Tam
RESUMEN

Understanding cellular metabolism holds immense potential for developing new classes of therapeutics that target metabolic pathways in cancer. Metabolic pathways are altered in bulk neoplastic cells in comparison to normal tissues. However, carcinoma cells within tumors are heterogeneous, and tumor-initiating cells (TICs) are important therapeutic targets that have remained metabolically uncharacterized. To understand their metabolic alterations, we performed metabolomics and metabolite tracing analyses, which revealed that TICs have highly elevated methionine cycle activity and transmethylation rates that are driven by MAT2A. High methionine cycle activity causes methionine consumption to far outstrip its regeneration, leading to addiction to exogenous methionine. Pharmacological inhibition of the methionine cycle, even transiently, is sufficient to cripple the tumor-initiating capability of these cells. Methionine cycle flux specifically influences the epigenetic state of cancer cells and drives tumor initiation. Methionine cycle enzymes are also enriched in other tumor types, and MAT2A expression impinges upon the sensitivity of certain cancer cells to therapeutic inhibition.